Open AccessErratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty‐eight–week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled study
Author(s) -
Kremer Joel,
Ritchlin Christopher,
Mendelsohn Alan,
Baker Daniel,
Kim Lilianne,
Xu Zhenhua,
Han John,
Taylor Peter
Publication year - 2010
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.27747
Subject(s) - golimumab , medicine , rheumatoid arthritis , placebo , gastroenterology , etanercept , pathology , alternative medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom